European Union antitrust regulators want more power to investigate Chinese companies benefiting from State subsidies seeking to acquire EU firms because of the distortive effect of such aid, Reuters reported.
The move comes as officials worry about Chinese and other foreign companies acquiring European champions with cutting edge technologies, especially those weakened by the coronavirus pandemic.
The European Commission, which can vet subsidies provided by EU governments but has no power over foreign State aid, has told EU countries that it wants to prepare the ground for a legal instrument to ensure a level playing field, the person said.
EU competition enforcers want to look at all cases involving a foreign State-subsidised company and have the power to launch an investigation. That would include in both merger and non-merger cases.
The planned legislation would complement the bloc’s foreign investment screening tool adopted in April which allows EU countries to intervene in cases of foreign direct investment in strategic assets, in particular if carried out by state-controlled or state-financed enterprises.
European Competition Commissioner Margrethe Vestager will present her proposal known as the white paper on foreign subsidies on June 17.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Judge Signals Revisions Likely in DOJ Case Targeting Live Nation Monopoly
Jan 22, 2025 by
CPI
American Airlines and JetBlue Agree to $2 Million Legal Fee Settlement with U.S. States
Jan 22, 2025 by
CPI
Federal Judge Dismisses Class Action Alleging Inflated Yacht Commission Fees
Jan 22, 2025 by
CPI
Doug Gurr Appointed Interim Chairman of UK’s Competition Authority
Jan 22, 2025 by
CPI
LinkedIn Faces Lawsuit Over Alleged Misuse of Customer Data for AI Training
Jan 22, 2025 by
Amanda Adams
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan